IA
PCVX icon

IFP Advisors’s Vaxcyte PCVX Stock Holding History

IFP Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6K Buy
560
+236
+73% +$12.8K ﹤0.01% 2666
2026
Q1 		$18.8K Sell
324
-1,271
-80% -$69K ﹤0.01% 2813
2025
Q4 		$73.6K Sell
1,595
-12
-0.7% -$537 ﹤0.01% 1978
2025
Q3 		$57.9K Sell
1,607
-2
-0.1% -$66 ﹤0.01% 2008
2025
Q2 		$52.7K Sell
1,609
-44
-3% -$1.44K ﹤0.01% 2023
2025
Q1 		$62.4K Buy
1,653
+1,306
+376% +$104K ﹤0.01% 1782
2024
Q4 		$28.4K Buy
347
+51
+17% +$5.06K ﹤0.01% 2091
2024
Q3 		$33.9K Buy
296
+17
+6% +$1.53K ﹤0.01% 1898
2024
Q2 		$21.1K Buy
+279
New +$19K ﹤0.01% 2058

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

IFP Advisors's PCVX Position: Q2 2026 in Review

IFP Advisors increased its Vaxcyte (PCVX) stake by 73% in Q2 2026, buying an estimated $12.8K and bringing the position to 560 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

IFP Advisors first reported a position in PCVX in Q2 2024 and has held it in 9 quarters since. The position peaked at $73.6K in Q4 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • IFP Advisors held 560 shares of Vaxcyte worth $32.6K as of Q2 2026.
  • IFP Advisors bought 236 Vaxcyte shares in Q2 2026, an estimated $12.8K.
  • Vaxcyte made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2666 holding.
  • IFP Advisors first reported a position in Vaxcyte in Q2 2024 and has held it in 9 quarters since.
  • IFP Advisors's Vaxcyte position peaked at $73.6K in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.